Lenalidomide for bortezomib-resistant multiple myeloma

Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / adverse effects
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Drug Resistance, Neoplasm
  • Health Status Indicators
  • Humans
  • Lenalidomide
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Peripheral Nervous System Diseases / chemically induced*
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use
  • Pyrazines / adverse effects
  • Pyrazines / therapeutic use*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide